Checkmate Pharmaceuticals

Checkmate Pharma is a clinical-stage biopharmaceutical company developing a new approach for cancer immunotherapy. The clinical programs are focused on enabling more people with cancer to benefit from the promise of novel immunotherapies. They leveraging their expertise in the field of CpG oligonucleotides to discover and develop immunotherapies designed to increase the efficacy of existing immunotherapies and to provide new treatment options for patients and their healthcare providers. Checkmate Pharmaceutical was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals

XOMA

Ad-hoc announcement pursuant to Article 53 of the SIX listing rules

Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment

CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc.  (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the University of Iowa Holden Comprehensive Cancer Center's presentation of preliminary data from an investigator-sponsored phase 1/2 trial evaluating vidutolimod, a first-in-class, immunostimulatory, noninfectious virus-like particle (VLP) containing a CpG-A Toll-like receptor 9 (TLR9) agonist. The early phase trial is investigating intratumoral vidutolimod therapy in combination with intravenous pembrolizumab in patients with relapsed lymphoma. The objective of this study is to determine the dose of vidutolimod that, in combination with pembrolizumab, has optimal clinical efficacy and acceptable toxicity in patients with relapsed lymphoma who have failed at least one line of therapy. In addition to the funding provided by Checkmate, the ongoing study is supported by NCI grant P50 CA97274 to the University of Iowa/Mayo Clinic (UI/MC) Lymphoma SPORE (specialized program of research excellence).

University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Checkmate Pharmaceuticals, Inc. (NasdaqGM: CMPI) to Regeneron Pharmaceuticals, Inc. (NasdaqGS: REGN). Under the terms of the proposed transaction, shareholders of Checkmate will receive only $10.50 in cash for each share of Checkmate that they own. KSF is seeking to determine whether this consideration and the

CHECKMATE PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI

New York, New York--(Newsfile Corp. - May 16, 2022) - Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Checkmate Pharmaceuticals, Inc. (CMPI), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms...

The M&A Class Action Firm Continues the Investigation of Checkmate Pharmaceuticals, Inc. - CMPI

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced first quarter 2022 financial results and provided a business update.

Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

Antares Pharma

PS Business Parks

Vidler Water Resouces

NEW YORK , May 9, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) 's  sale to Regeneron Pharmaceuticals, Inc. for $10.50 per share in cash. If you are a Checkmate shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CMPI, PSB, ATRS, VWTR

CHECKMATE PHARMACEUTICALS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkmate Pharmaceuticals, Inc. - CMPI

Twitter

NEW YORK , April 26, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: PS Business Parks, Inc. (NYSE: PSB)'s sale to affiliates of Blackstone Real Estate for $187.50 per share in cash. If you are a PS Business Parks shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates PSB, FSI, TWTR

Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) shares are up 300% after the clinical-stage company focusing on novel tech harnessing the immune system's power in the fight against cancer announced a definitive agreement to be acquired by Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Regeneron will acquire Checkmate's common shares for $10.5 per share for almost $250 million.

Here is why Checkmate shares surged 300%

Wilmington, Delaware--(Newsfile Corp. - April 20, 2022) - Rigrodsky Law, P.A. is investigating Checkmate Pharmaceuticals, Inc. ("Checkmate") (NASDAQ: CMPI) regarding possible breaches of fiduciary duties and other violations of law related to Checkmate's agreement to be acquired by Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Under the terms of the agreement, Checkmate's shareholders will receive $10.50 in cash for each share of Checkmate common stock they own.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-checkmate-pharmaceuticals-inc.To...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Checkmate Pharmaceuticals, Inc. Buyout

NEW YORK , April 19, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Checkmate Pharmaceuticals, Inc. ("Checkmate" or the "Company") (NASDAQ: CMPI), in connection with the proposed acquisition of the Company by Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), via a tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $10.50 in cash for each share of Checkmate common stock owned.

SHAREHOLDER ALERT: Weiss Law Investigates Checkmate Pharmaceuticals, Inc.

Checkpoint Pharmaceuticals lands a premium-rich buyout offer from biotech heavyweight Regeneron.

Why Checkmate Pharmaceuticals Stock Is Rocketing Higher Today

Checkmate Pharmaceuticals (CMPI) stock is rocketing higher on Tuesday following news that Regeneron Pharmaceuticals (REGN) is acquiring it. The post Why Is Checkmate Pharmaceuticals (CMPI) Stock Up 300% Today?

Why Is Checkmate Pharmaceuticals (CMPI) Stock Up 300% Today?

MILWAUKEE , April 19, 2022 /PRNewswire/ -- Ademi LLP is investigating Checkmate (NASDAQ:CMPI) for possible breaches of fiduciary duty and other violations of law in its transaction with Regeneron.  Click here to learn how to join the action: https://www.ademilaw.com/case/checkmate-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Checkmate Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Regeneron

Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) shares are trading higher by 328.40% to $10.41 during Tuesday's pre-market session after Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a deal to acquire the company for $10.50 per share in cash. Checkmate's lead investigational candidate.

Why Checkmate Pharmaceuticals Shares Are Skyrocketing

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) will acquire Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) for $10.50 per share, equivalent to a total equity value of approximately $250 million. Checkmate is a clinical-stage biopharmaceutical company focused on proprietary.

Checkmate Pharma Shares Skyrocket Over 300% On Regeneron $250M Acquisition Deal

Aytu BioScience

Toughbuilt Industries Inc

Here's what you need to know about trading penny stocks on April 19th The post Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320%

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) to Regeneron Pharmaceuticals, Inc. for $10.50 per share in cash is fair to Checkmate shareholders. Halper Sadeh encourages Checkmate shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation

CMPI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Checkmate Pharmaceuticals, Inc. Is Fair to Shareholders

Proposed ~$250 million all-cash acquisition strengthens Regeneron's portfolio of diverse and combinable immuno-oncology candidates Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical responses observed in PD-1 refractory melanoma as monotherapy Vidutolimod is currently being studied in combination with other agents for melanoma, non-melanoma skin cancers, and head and neck cancer TARRYTOWN, N.Y. and CAMBRIDGE, Mass.

Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types

CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc.  (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the presentation of biomarker signature data from two studies evaluating vidutolimod, a first-in-class, immunostimulatory, noninfectious virus-like particle (VLP) containing a CpG-A Toll-like receptor 9 (TLR9) agonist. The first study evaluated vidutolimod in patients with advanced anti-PD-(L)1 refractory melanoma who received intratumoral vidutolimod monotherapy or in combination with intravenous pembrolizumab, and the second evaluated patients with anti-PD-(L)1 refractory non-small cell lung cancer (NSCLC) who received vidutolimod and atezolizumab. The objective of these analyses was to identify transcriptional signatures specific to the antitumor activity of treatment with vidutolimod monotherapy or in combination with PD-1 blockade in these two subsets.

Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Alan Bash, experienced biopharmaceutical executive, appointed President and CEO

Checkmate Pharmaceuticals Announces Full Year 2021 Financial Results and Provides Business Update

Adagene

Amgen

Gritstone Oncology Inc

Eli Lilly

Given that developing biotechnology companies are more susceptible to swings in stock price than established ones, investors might want to keep an eye on happenings at next month's American Association for Cancer Research Annual Meeting in New Orleans. Of the eight public companies that will discuss clinical trial results, half qualify as small caps or lesser.

Investors Hoping for News at Cancer Meeting That Will Boost Share Prices

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc.  (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that it will present biomarker data at the 2022 American Association for Cancer Research (AACR) Annual Meeting taking place in New Orleans, Louisiana from April 8-13, 2022. An e-poster will be made available online starting Friday, April 8 at 1:00pm ET.

Checkmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Accomplished global biopharmaceutical executive with over 20 years of strategic and operational leadership at Bristol Myers Squibb Accomplished global biopharmaceutical executive with over 20 years of strategic and operational leadership at Bristol Myers Squibb

Checkmate Pharmaceuticals Appoints Alan Bash as President and CEO

CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the addition of Jon Wigginton, M.D. to its Board of Directors (“Board”).

News for Checkmate Pharmaceuticals Stock (CMPI)